ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — Technical Presentation (November 2012)

10 slides from ReShape Lifesciences's technical presentation, Nov 13, 2012

  1. Slide 1: Intermittent Neural Transmission Block Of The Intra-abdominal Vagus Induces Sustained Blood Pressure Reduction In Obese Subjects

    Abstract 13195 Katherine S Tweden, PhD a , Mark B Knudson, PhD a , Scott A Shikora, MD b , Robert M Carey, MD a EnteroMedics, Inc, St. Paul, MN; b Brigham and Women’s Hospital, Boston, MA; c University of Virginia Health System, Charlottesville, VA Intermittent Neural Transmission Block Of The Intra

  2. Slide 2: Financial Disclosures

    Financial Disclosures This clinical trial was completely funded by EnteroMedics Inc., St. Paul, MN, USA

  3. Slide 3: Background

    Background • Intermittent block of the intra-abdominal vagus (VBLOC) using an implantable device has been shown to cause significant EWL in obese subjects. • We tested the hypothesis that VBLOC would improve blood pressure (BP) prior to significant WL in obese subjects with a diagnosis of hypertensi

  4. Slide 4: Methods

    Methods BP was measured at baseline, weekly to 4 wk and monthly to 12 mo during a randomized, controlled trial to evaluate weight loss in 294 obese subjects. HT was defined by JNC-7 guidelines (group A) or if subjects had HT history (group B); the analysis was performed in a subset of subjects who h

  5. Slide 5: Demographics

    Demographics Group A Subjects with elevated BP Group B Subjects with history of HT n BMI (kg/m ) 41±1 41±1 Age (years) 50±1 51±1 Female/Male Ratio

  6. Slide 6: Change in SBP and DBP and %EWL Over Months

    Change in SBP and DBP and %EWL Over 12 months Figure 2: Relationship of Change in SBP (mmHg) to 12 Months Compared to %EWL (Group B) Figure 3: Relationship of Change in DBP (mmHg) to 12 Months Compared to %EWL (Group B)

  7. Slide 7: SBP and DBP Reduction Compared to %EWL at 6 Months

    SBP and DBP Reduction Compared to %EWL at 6 months Fig 4: Relationship of Change in SBP (mmHg) at 6 Months Compared to %EWL (Group B), p=0.52, r=0.09 Fig 5: Relationship of Change in DBP (mmHg) at 6 Months Compared to %EWL (Group B), p=0.82, r=0.03

  8. Slide 8: SBP and DBP Reduction Compared to Baseline BP at 12 Months

    SBP and DBP Reduction Compared to Baseline BP at 12 mo Figure 6: Relationship of Change in SBP (mmHg) at 12 Months Compared to Baseline (Group B), p<0.0001, r= -0.6 Figure 7: Relationship of Change in DBP (mmHg) at 12 Months Compared to Baseline (Group B), p<0.0001, r= -0.61

  9. Slide 9: Discussion

    Discussion • Change in BP in hypertensive subjects and subjects with elevated BP occurred prior to weight loss and was sustained to 12 months • BP reduction was independent of weight loss magnitude • Higher baseline values of BP were associated with larger reductions in BP levels

  10. Slide 10: Conclusions

    Conclusions • VBLOC induced clinically significant, sustained BP reduction at 1 year in obese subjects with a history of HT or elevated BP prior to therapy. • These data suggest that VBLOC therapy may offer major non-pharmacologic BP reduction for obese subjects with HT. • These findings will need t

EnteroMedics — Technical Presentation (November 2012) on 6ix